Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2006-10-18
2009-10-27
Blanchard, David J. (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S138100, C424S139100, C424S178100, C424S183100
Reexamination Certificate
active
07608259
ABSTRACT:
Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer treatment and reduce the likelihood of clinical relapse after treatment.
REFERENCES:
patent: 5169835 (1992-12-01), Chan
patent: 5489516 (1996-02-01), Broudy et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5730982 (1998-03-01), Scheinberg
patent: 5808002 (1998-09-01), Buhring
patent: 5843633 (1998-12-01), Yin et al.
patent: 5869045 (1999-02-01), Hellstrom et al.
patent: 5980896 (1999-11-01), Helstrom et al.
patent: 6129915 (2000-10-01), Wels et al.
patent: 6258939 (2001-07-01), Reiter et al.
patent: 6455678 (2002-09-01), Yin et al.
patent: 6506881 (2003-01-01), Adair et al.
patent: 6767737 (2004-07-01), Wilson et al.
patent: 6852533 (2005-02-01), Raffi et al.
patent: 7011947 (2006-03-01), Golub et al.
patent: 7030228 (2006-04-01), Schmitz et al.
patent: 7101707 (2006-09-01), Castellon
patent: 7192769 (2007-03-01), Pykett et al.
patent: 7238777 (2007-07-01), Itoh et al.
patent: 7361336 (2008-04-01), Bergstein
patent: 7427400 (2008-09-01), Bergstein
patent: 2001/0055751 (2001-12-01), Reiter et al.
patent: 2005/0010042 (2005-01-01), Ruben et al.
patent: 2005/0214861 (2005-09-01), Yin et al.
patent: 2007/0036803 (2007-02-01), Bergstein
patent: 2007/0036804 (2007-02-01), Bergstein
patent: 2007/0041984 (2007-02-01), Bergstein
patent: WO 90/12885 (1990-11-01), None
patent: WO 94/07474 (1994-04-01), None
patent: WO 95/07348 (1995-03-01), None
patent: WO 97/22360 (1997-06-01), None
patent: WO 97/35614 (1997-10-01), None
patent: WO 00/40229 (2000-07-01), None
patent: WO 02/40717 (2002-05-01), None
patent: WO 03/016470 (2003-02-01), None
Gura, T. Systems for identifying new drugs are often faulty. Science, 1997. vol. 278, pp. 1041-1042.
Richardson, Robson, Lang, Neal, Maitland, and Collins. CD133, a novel marker for human prostatic epithelial stem cells. Journal of Cell Science, 2004. vol. 117, pp. 3539-3545.
Florek, M., Haase, M., Marzesco, A., Freund, D., Ehninger, G., Huttner, W.B., and Corbell, D. Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Research, 2005. vol. 319, pp. 15-26.
Bello and Sotomayer. Novel immunotherapeutic approaches for lymphomas. American Society Hematology Educ. Program, 2007. pages 233-242.
Hatake, Tokudome, and Ito. Tanstuzumab treatment for breast cancer. Internal Medicine, 2007. vol. 46, pp. 149-150.
Definition of solid tumor. National Cancer Institute Dictionary of Cancer Terms, 2009. http://www.cancer.gov.
Berezovska et al., 2000, “Rapid Notch1 nuclear translocation after ligand binding depends on presenilin-associated gamma-secretase activity,” Ann. N. Y. Acad. Sci. 920:223-6 (abstract).
Bodey et al., 2000, “Failure of cancer vaccines: the significant limitations of this approach to immunotherapy,” Anticancer Res. 20(4):2665-76.
Bonnet et al., 1997, “Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell,” Nat. Med. 3(7):730-7.
Boucher et al., 1995, “The expression of trophoblastic cell markers by lung carcinomas,” Hum. Pathol. 26(11):1201-6.
Chen et al., 1997, “Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells,” Blood 89(9):3345-53.
Cripps et al., 2002, “Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study,” Clin. Cancer Res. 8(7):2188-92.
Door, 1997, “Three A's of repopulation during fractionated irradiation of squamous epithelia: Asymmetry loss, Acceleration of stem-cell divisions and Abortive divisions,” Int. J. Radiation Biol. 72(6):635-643.
Eck et al., 1996, “Gene-Based Therapy,” The Pharmacological Basis of Therapeutics, Goodman and Gillman, Eds., pp. 77-10.
Grim et al., 1998, “Intracellular expression of the anti-erbB-2 sFv N29 fails to accomplish efficient target modulation,” Biochem. Biophys. Res. Commun. 250(3):699-703.
Haynes et al., 1985, “The ultrastructural immunohistochemistry of oncofoetal antigens in large bowel carcinomas,” Virchows. Arch. A Pathol. Anat. Histopathol. 405(2):263-75.
Heikinheimo et al., 1987, “Oncoplacental protein SPI—a constitutive and inducible late differentiation marker of the human myelomonocytic lineage,” Blood 70(5):1279-83.
Hope et al., 2003, “Human acute myeloid leukemia stem cells,” Arch. Med. Res. 34(6):507-14.
James et al., 1998, “The therapeutic potential of ribozymes,” Blood 91(2):371-82.
Jones et al., 1998, “Antibodies for targeted gene therapy: extracellular gene targeting and intracellular expression,” Adv. Drug. Delivery Reviews 31:153-170.
Lin et al., 1997, “Neuroblasts: a model for the asymmetric division of stem cells,” Trends Genetics 13(1):33-39.
Marshall et al., 2004, “A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer,” Clin. Colorectal Cancer 4(4):268-74.
Metcalf, 1983, “Early events in the suppression of myeloid leukemic cells by biological regulators,” Haematol. Blood Transfus 28:320-6.
Miraglia et al., 1997, “A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning,” Blood 90(12):5013-21.
Miyamura et al., 1991, Sapporo Igaku Zasshi 60:183-196 (abstract).
Mizutani, 1990, Sapporo Medical Journal 59:345-356 (abstract).
Moroz et al., 1993, “Oncoprecipitins: A novel type of natural substances and oncofetal antigens,” Pure and Appl. Chem. 65(6):1253-1264.
O'Brien et al., Recent Clinical Developments in Gynecologic Oncology, Paul Morrow et al., Ed., pp. 167-180.
Orkin et al., 1995, “Report and Recommendation of the Panel to Assess the NIH Investment in Research on Gene Therapy,” NIH.
Otto et al., 1997, “Lung stem cells,” Int. J. Exp. Pathol. 78(5):291-310.
Oza et al., 2003, “Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116),” Gynecol. Oncol. 89(1):129-33.
Passegue et al., 2003, “Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?,” Proc. Natl. Acad. Sci. U. S. A. 100 Suppl 1:11842-9.
Rooney et al., 1988, “Molecular cloning of a cDNA for human pregnancy-specific beta 1-glycoprotein:homology with human carcinoembryonic antigen and related proteins,” Gene 71(2):439-49.
Sachs, 1991, “The control of growth and differentiation in normal and leukemic blood cells,” Cancer 67(S10):2684-2694.
Sakakibara et al., 1996, “Mouse-Musashi-1, a neural RNA-binding protein highly enriched in the mammalian CNS stem cell,” Dev. Biol. 176(2):230-42.
Schlom, 1991, Molecular foundations of Oncology, Samuel Broder, Ed., pp. 95-134.
Schultze et al., 2004, “DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy,” Trends Immunol. 25(12):659-64.
Sherley et al., 1995, “Expression of the wild-type p53 antioncogene induces guanine nucleotide-dependent stem cell division kinetics,” Proc. Natl. Acad. Sci. U. S. A. 92(1):136-40.
Shtalrid et al., 1987, “Review of clinical and haematological response to low-dose cytosine arabinoside in acute myeloid leukaemia,” Eur. J. Haematol. 38(1):3-11.
Stedman's Medical Dictionary, 27thEdition, 1985.
Taichman et al., 2002, “Notch1 and Jagged1 expression by the developing pulmonary vasculature,” Dev. Dyn. 225(2):166-75 (abstract).
Ten Have-Opbroek et al., 1997, &#
Blanchard David J.
Day Jones
Gussow Anne M.
LandOfFree
Methods of cancer diagnosis and therapy targeted against a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of cancer diagnosis and therapy targeted against a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of cancer diagnosis and therapy targeted against a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4095619